als PDF

Prof. Dr. med. Peter Alexander Bartenstein
1. General Information
Name
Peter Alexander Bartenstein, Prof. Dr. med.
Date of Birth
19.08.1959
Place of Birth
Nürnberg, Germany
Gender
Male
Address
Klinik und Poliklinik für Nuklearmedizin, Ludwig-Maximilians-Universität München,
Marchioninistr. 15, 81377 München
Phone
+ 49 89 7095 4610
E-mail
[email protected]
Current Position
W3-Professorship, Director of the Department for Nuclear Medicine, LMU München
2. University education
1980 – 1985
Studies in Human Medicine, University Bonn
1978 – 1980
Studies in Human Medicine, University Bochum
3. Scientific degrees / Board certification
1994
Habilitation in Nuclear Medicine, Universität Münster (Advisor: Prof. Dr. Dr. O. Schober)
1985
Doctoral Thesis, Universität Bonn (Advisor: Professor Dr. L. Labedzki)
4. Other scientific degree
None
5. Professional Development (Post University Degree)
Since 09/2006
Director of the Department of Nuclear Medicine, LMU, München
02/1999 – 08/2006
Director of the Department of Nuclear Medicine, Johannes Gutenberg- Universität, Mainz
04/1994 – 01/1999
Senior physician, Department of Nuclear Medicine, Klinikum rechts der Isar, TUM
09/1991 – 04/1994
Senior physician, Department of Nuclear Medicine, Universitätsklinikum Münster
09/1990 – 08/1991
Research Fellow (DFG) PET-Group MRC Cyclotron Unit, Hammersmith Hospital London
05/1986 – 08/1990
Senior physician, Department of Nuclear Medicine, Universitätsklinikum Münster
07/1985 – 05/1986
Stabsarzt in Andernach
6. Miscellaneous (Honors, Awards, Others)
4
Since 11/2009
Coordinator LMU for the Spitzencluster m (BMBF)
Since 02/2007
Chairman of the PhD Examination Committee
06/2002 – 08/2006
Leader of the key area Neuroscience, Universität Mainz
7. Publications
Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, RodriguezArabaolaza I, Ramirez JC, Torres-Ruíz R, Garcia E, Hidalgo M, Cebrián DÁ, Heuchel R, Löhr M, Berger F,
Bartenstein P, Aicher A, Heeschen C. Nodal/Activin signaling drives self-renewal and tumorigenicity of
pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433446
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Bürger K, Hiemeyer F, Wittemer- Rupp S, Seibyl J,
Reininger C, Sabri O. Cerebral amyloid-β PET with florbetaben ((18)F) in patients with Alzheimer's disease
and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurology 2011; 10: 424-435
Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz HG, Smolka MN, Gründer G, Cumming
P, Yoshitaka Kumakura Y, Bartenstein P, Dolan RJ, Heinz A. Dopamine storage capacity in the amygdala
gates processing of aversive stimuli in amygdala and anterior cingulate cortex: a combined PET – fMRI study
Nat Neurosci 2008; 11:1381-1382
Heinz A, Siessmeier T, Wrase J, Buchholz HG, Gründer G, Kumakura Y, Cumming P, Schreckenberger M,
Smolka MN, Rösch F, Mann K, Bartenstein P. Correlation of Alcohol Craving With Striatal Dopamine
Synthesis Capacity and D2/3 Receptor Availability: A Combined [18F]DOPA and [18F]DMFP PET Study in
Detoxified Alcoholic Patients Am J Psychiatry 2005;162: 1515-1520
8. Patents
None